On January 5, 2023 Hubro Therapeutics reported that Mr. Geir Hetland will take on the position as CFO of the company effective from early 2023 (Press release, Hubro Therapeutics, JAN 5, 2023, View Source [SID1234625879]). Mr. Hetland transits from position as CFO at Thermo Fisher Scientific (previously Dynal Biotech) in Norway. Mr. Hetland brings an extensive background from the biotechnology industry in the EU and US. Mr. Hetland has previously held positions as CFO of AstraZeneca and has broad experience including finance, budget planning, marketing operations, integration and strategic planning. Mr. Hetland will join the company’s executive leadership group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!